Professor Julien Chaisse, an associate member of CCCL, explains that laboratories producing anti-COVID-19 vaccines, such as Pfizer and Moderna, have been facing a wave of political mobilization to abandon their rights. For its supporters, only a measure of this type will quickly produce enough vaccines, especially in the poorest countries. However, the niche promises to be particularly competitive, with many projects underway, which limits the risk that a limited number of players paralyze the market with their patents. Read the full article here: Julien Dury, “Lever les brevets anti-COVID ? Peu probable et pas forcément souhaitable”, Journal de Montreal, 10 February 2021 <https://www.journaldemontreal.com/2021/02/10/lever-les-brevets-anti-covid--peu-probable-et-pas-forcement-souhaitable>.